AlloMap^®

XDx has developed and launched AlloMap^® Molecular Expression Testing for heart transplant patient management. For more info, click here.

What’s new?

To get the latest updates on the IMAGE clinical trial, click here.

XDx

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. The company has developed a proprietary method of utilizing gene expression in blood that provides a new tool for physicians to manage the care of heart transplant patients.

The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.

Updates